C Assistant

Christopher R. Herzog, PhD

Maytown, PA . Tel 717-***-**** . acch92@r.postjobfree.com

SENIOR SCIENTIST

Core qualifications:

. Deep knowledge of cancer biology, cancer genetics and genomics,

biomarker discovery and validation, and the molecular mechanisms of

cancer and cancer treatment.

. 12 years of experience leading independent cancer research as

Assistant Professor or equivalent discovering insights into

oncogenesis - e.g. discovered novel lung tumor suppressors and

molecular biomarkers; discovered carcinogen-induced genomic

instability as a causal mechanism of lung cancer.

. Strong awareness and understanding of biomarker and personalized

medicine research and drug-diagnostic co-development.

. 9 funded grants; 26 peer-reviewed publications, majority as lead or

senior author.

. Skilled mentor, trainer and teacher with 8+ years of experience

teaching graduate courses, training staff, and mentoring graduate

students.

. Skilled in statistical analysis and interpretation of basic and

translational data.

. Record of establishing and maintaining cross-functional collaborations

to achieve goals.

. Hands-on BSL2 laboratory scientist with broad technical, data analysis

and experimental design skill set in molecular and cellular methods

including molecular cloning, cell-based assays, transfection, RNAi,

expression and genomics microarrays, RT-PCR, and next generation

sequencing.

. Experienced in developing approved clinical trials; knowledgeable of

drug development process and regulations; GLP/GMP.

CAREER HISTORY

CANCER MANAGEMENT CONSULTANT

2014

. Consults patients and physicians on the interpretation of diagnostic

results including next generation sequencing, cancer panels, and

personalized treatment options.

Thomas Jefferson University Hospital, Philadelphia, PA

*2013

GENOMICS PROGRAM MANAGER, CLINICAL LABORATORIES

. Clinical laboratory position responsible for initiating and managing

projects to develop and validate clinical genomic applications

including cancer gene panels, mutation detection, and whole genome

copy number variation analysis for personalized cancer treatment, and

molecular diagnosis of cancer and heritable developmental disease.

. Qualifying experience as lab/program leader with proficiency in

various genomics methods including Sanger sequencing, RT-PCR, next

generation sequencing, chromosomal microarray analysis, genomic

databases and browsers (NCBI, OMIM, UCSC, ENSEMBL, etc.).

*Resigned from this position of own accord after several months to pursue

an opportunity in cancer R&D.

Penn State College of Medicine, Penn State Cancer Institute, Hershey, PA

2004 - 2012

assistant professor, department of pharmacology

. Established and led an independent and collaborative research program

on the molecular basis of lung cancer with objectives of identifying

and validating new therapeutic targets and clinical biomarkers.

. Principal Investigator/author of 4 grant proposals over span of 6

years.

. Identified FOXO3 and ADSS1 as novel candidate lung tumor suppressor

genes based on recurrent copy number loss; designed and published

studies validating roles as lung tumor suppressors.

. Developed approved phase 4 clinical trial study examining the effect

of DNA copy number loss of FOXO3 and ADSS1 on advanced lung

adenocarcinoma treatment outcome.

. Created an environment of high performance; trained and mentored PhD

graduates who have advanced to positions at prestigious research

institutions including Dana-Farber Cancer Institute and the Fox Chase

Cancer Center.

Institute for Cancer Prevention (previously American Health Foundation),

Valhalla, NY 2000 - 2004

associate research scientist, divisions of Cancer Susceptibility,

chemoprevention and nutritional carcinogenesis, AND Mechanisms of

Carcinogenesis

. Recruited as Principal Investigator to bridge knowledge of cancer

genetics with the Institute's internationally recognized expertise in

the prevention of cancer; recruited into several of the Institute's

NCI-funded Programs.

. Established an independent research program studying the molecular

basis of lung cancer.

. Demonstrated that carcinogens induce chromosome instability as a

causal mechanism underlying lung cancer in an in vivo mouse model for

lung carcinogenesis.

. Contributed independent and collaborative research efforts generating

original published work on the mechanisms of lung carcinogenesis and

the role of diet in cancer prevention.

. Co-investigator, co-author of awarded peer-reviewed grant proposals.

additional experience

Research Assistant Professor, Department of Pathology, Medical College of

Ohio 1996 - 2000

. Scientist in lab reputed for mouse models of lung carcinogenesis;

managed laboratory research activities, lectured for graduate courses,

and trained graduate students.

. Discovered role of Cdkn2a tumor suppressor genetic variant in lung

cancer susceptibility and disease progression.

. Co-investigator, co-author of awarded peer-reviewed grant proposals.

Post-doctoral Fellow, Department of Pathology, Medical College of Ohio

1995 - 1996

. Published author on studies on the molecular basis of lung

carcinogenesis.

AWARDED GRANTS

Eastern Cooperative Oncology Group Initiated Clinical Trial: Randomized

Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a

Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel

and Bevacizumab for Advanced Non-Squamous NSCLC. Project: Evaluation of

ADSS1 and FOXO3a as Predictors of Treatment Outcome in Non-Squamous NSCLC

Role: Project Co-Principal Investigator

02/01/11-07/01/12

ADSS1 Inactivation as a Promoter of Tumor Metabolism and Lung

Carcinogenesis

NIEHS R21 ES017145-01

Role: Principal Investigator

07/01/09-06/30/11

In Vivo Targeting of AMP Synthesis in Lung Cancer with Nanoliposome-

Protected siRNA

PSU College of Medicine - Deans Feasibility Grant

Role: Principal Investigator

07/01/08-06/31/09

Role of FOXO3a in Lung Cancer Therapy

Joan's Legacy Foundation

Role: Principal Investigator

01/01/07-12/31/08

HMG-CoA Reductase and Cox-2 Inhibitors in Colon Cancer (Principal

Investigator, Rao)

NCI R01: CA94962

Role: Co-investigator

08/01/04-07/31/09

Prevention of Colorectal Cancer iNOS and COX-2 Inhibitors (Principal

Investigator, Rao)

NCI R01: CA109247

Role: Co-investigator

04/01/02-03/31/07

Molecular Genetics of Mouse Lung Tumors (Principal Investigator, You)

NCI R01: CA58554-06

Role: Co-investigator

07/01/98-6/30/03

Genetic Resistance to Mouse Lung Carcinogenesis (Principal Investigator,

You)

NCI R01: CA78797-01

Role: Co-investigator

07/01/98-6/30/03

Altered Gene Expression in Rat Mammary and Mouse Lung Tumors (Principal

Investigator, You)

NCI CN75108

Role: Co-investigator

06/30/97-06/29/99

PUBLICATIONS

1. Schut, H.A.J. and, Herzog, C.R. Formation of DNA adducts of 2-amino-1-

methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in male Fischer-344 rats.

Cancer Letters, 67:117-124, 1992.

2. Herzog, C.R., Schut, H.A.J., Maronpot, R.R., and You, M. Ras mutations

in 2-amino-3-methylimidazo[4,5-f]quinoline-induced CDF1 tumors. Molecular

Carcinogenesis, 8: 202-207, 1993.

3. Schut, H.A.J., Herzog, C.R., and Cummings, D.A. Accumulation of DNA

adducts of 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) in tissues and

white blood cells of the Fischer-344 rat after multiple oral dosing with

IQ. Carcinogenesis, 15: 1467-1470, 1994.

4. Herzog, C.R., Wiseman, R.W., and You, M. Deletion mapping of a putative

tumor suppressor gene on chromosome 4 in mouse lung tumors. Cancer

Research, 54: 4007-4010, 1994.

5. Herzog, C.R., Wang, Y., You, M. Allelic loss of distal chromosome 4 in

mouse lung tumors localize a putative tumor suppressor gene to a region

homologous to human chromosome 1p36. Oncogene, 11: 1811-1815, 1995.

6. Herzog, C.R., Wang, Y., Schut, H.A.J., and You, M. Frequent loss of

heterozygosity on chromosome 1, 11, 12, and 14 in hybrid mouse lung

adenocarcinomas. Molecular Carcinogenesis, 16: 83-90, 1996.

7. Herzog, C.R., Soloff, E.V., McDoniels, A. L., Tyson, F.L. Malkinson, A.,

Haugen-Strano, A., Wiseman, R.W., Anderson, M.W., and You, M. Homozygous

codeletion and differential decreased expression of p16INK4a-alpha,

p16INK4a-beta and p15INK4b in mouse lung tumor cells. Oncogene, 13: 1885-

1891, 1996.

8. Soloff, E. V, Herzog, C. R., and You, M. The 5'-flanking region of the

mouse E1-alpha form of the p16INK4a (MTS1) gene. Gene, 180: 213-215,

1996.

9. Herzog, C. R. and You, M. Sequence variants and chromosomal mapping of

the murine Cdkn2a gene. Mammalian Genome, 8: 65-66, 1997.

10. Herzog, C. R., Lubet, R. A., You, M. Genetic and epigenetic

modifications in mouse lung tumorigenesis: implications for

chemoprevention. Journal of Cellular Biochemistry, S28/29: 49-63, 1997.

11. Sabourin, C. L. K., Wang, Q-S., Ralston, S. L., Evans, J., Coate, J.,

Herzog, C. R., Jones, S. L., Weghorst, C. M., Kelloff, G. J., Lubet, R.

A., You, M., and Stoner, G. D. Expression of cell cycle proteins in 4-

(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung tumors.

Experimental Lung Research, 24: 499-521, 1998.

12. Herzog, C. R., Noh, S., Lantry, L. E., Guan, K-L., and You, M. Cdkn2a

encodes functional variation of p16INK4a, but not p19ARF, which confers

selection in mouse lung tumorigenesis. Molecular Carcinogenesis, 25: 92-

98, 1999.

13. Herzog, C. R., Crist, K. A., Sabourin, C. L. K., Kelloff, G. J., Boone,

C. W., Stoner, G. D., and You, M. Analysis of chromosome 3p tumor

suppressor loci in cervical carcinomas. Molecular Carcinogenesis, 30: 159-

168, 2001.

14. McDoniels-Silvers, A. L., Herzog, C. R., Tyson, F. L., Malkinson, A.

M., and You, M. Inactivation of both RB and p53 pathways in mouse lung

epithelial cell lines. Experimental Lung Research, 27: 297-318, 2001.

15. Zhang, Z., Wang, Y., Herzog, C. R., DePinho, R. A., and You M. A strong

candidate for the Papgi locus on mouse chromosome 4 affecting lung tumor

progression. Oncogene, 21: 5960-5966, 2002.

16. *Herzog, C.R., Devereux, T.R., Pittman, B. and You, M. Carcinogen-

induction directs the selection of allelic losses during mouse lung

tumorigenesis. Cancer Research, 62: 6424-6429, 2002.

17. *Herzog, C. R. Chk2 meets Plk3 in damage control. Cell Cycle, 1: 408-

409, 2002.

18. Malisetty, V. S., Herzog, C. R., and Rao, C. V. Celecoxib inhibition of

COX-2 in colon cancer cell lines increases the nuclear localization of

functionally active p53. Cancer Research, 63: 5239-5242, 2003.

19. Chung, F-L., Schwartz, J., Herzog, C. R. and Yang, Y-M. Tea and cancer

prevention: Studies in animals and humans. J. Nutrition, 133: 3268S-

3274S, 2003.

20. Herzog, C. R., Malisetty, V. S., and Rao, C. V. Reply To

Correspondence: Axel Schonthal Ref: M.V. Swamy, et al. Inhibition of COX-

2 in colon cancer cell lines by celecoxib increases the nuclear

localization of active p53. Cancer Research, 63: 5239-42, 2004.

21. *Herzog, C. R., Bodon, N., Pittman, B., You, M., Anderson, M. W.,

Maronpot, R. R., Massey, T. E. and Devereux, T. R. Carcinogen-specific

targeting of chromosome 12 for loss of heterozygosity in mouse lung

adenocarcinomas: Implications for chromosome instability induction and

tumor progression. Oncogene, 23: 3000-3039, 2004.

22. *Herzog, C. R., Desai, D., and Amin, S. Array CGH analysis reveals

chromosomal aberrations in mouse lung adenocarcinomas induced by the

human lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.

Biochemical Biophysical Research. Communications, 341: 856-863, 2006.

23. Sun, Y. W., Herzog, C. R., Krzeminski, J., Amin, S., Perdew, G., El-

Bayoumy, K. Effects of the environmental mammary carcinogen 6-

nitrochrysene on p53 and p21(Cip1) protein expression and cell cycle

regulation in MCF-7 and MCF-10A cells. Chemical Biological

Interactactions, 170: 31-39, 2007.

24. Miller, J.C., Blake Jr., D.C., *Herzog, C.R. Adenylosuccinate

Synthetase 1 (ADSS1) is a novel target of deletion in lung adenocarcinoma

and associates with carcinogen-induced chromosome instability. Molecular

Carcinogenesis, 48: 1116-22, 2009.

25. *Herzog, C.R., Blake Jr., D.C., Mikse, O.R. Grigoryiva, L.S.,

Gundermann, E.L. FoxO3a gene is a target of deletion in mouse lung

adenocarcinoma. Oncology Reports, 22: 837-43, 2009.

26. Blake Jr., D.C., Mikse, O.R., Freeman, W.M., *Herzog, C.R. FOXO3a

stimulates a pro-apoptotic transcriptional program in response to human

lung carcinogen nicotine-derived nitrosaminoketone. Lung Cancer, 67: 37-

47, 2010.

27. Mikse, O.R., Blake Jr. D.C., Jones, N.R., Gallagher, C., Sun, Y-W.,

Amin, S., Lazarus, P., Weisz, J., *Herzog, C.R. FOXO3 encodes a

carcinogen-activated transcription factor that is frequently deleted in

early-stage lung adenocarcinoma. Cancer Research, 70: 6205-6216, 2010.

28. Mikse, O.R., Blake Jr., D.C., *Herzog, C.R. FOXO3a mitigates the

effects of microtubule inhibitors in lung adenocarcinoma (in

preparation).

29. Miller, J.C., Rajhans, R., Blake Jr., D.C., *Herzog, C.R.

Adenlylosuccinate synthetase 1 gene is deleted in early-stage lung

adenocarcinoma (in preparation).

* Senior author

37 published meeting abstracts

EDUCATION/PROFESSIONAL SERVICE

PhD, Biomedical Sciences (Cancer Genetics), Medical College of Ohio (now

University of Toledo), Toledo, OH; Dissertation: Genetic changes in lung

carcinogenesis; Major Advisor: Ming You, MD, PhD (1995)

MS, Biology (Genetics), University of Toledo, Toledo, OH (1989)

BA, Biology, University of Toledo, Toledo, OH (1985)

AD HOC REVIEWER (peer-reviewed journals)

American Journal of Pathology

Cancer Research

Carcinogenesis

Journal of the National Cancer Institute

Molecular Carcinogenesis

Nutrition and Cancer

Pharmaceutical Research

PROFESSIONAL AFFILIATIONS

American Association for Cancer Research

American Association for the Advancement of Science

National Lung Cancer Partnership

The Leukemia & Lymphoma Society

American Society for Biochemistry and Molecular Biology

LABORATORY SKILLS AND EXPERIENCE

. Cancer genetics and genomics - Sanger sequencing, next generation

sequencing, aCGH, chromosome microarray analysis, bioinformatics,

data mining, genomic databases, mutation/SNP databases (OMIN), genome

browsers (ENSEMBL, UCSC).

. PCR, RT-PCR, single-strand conformation polymorphism analysis (SSCP)

for detecting mutations and quantitating DNA copy number and gene

expression.

. Positional cloning, gene mapping/QTL analysis, genotyping.

. DNA and RNA manipulation; molecular cloning; site-directed

mutagenesis; vector design; DNA/promoter methylation; RNAi.

. Expression microarrays.

. Genetic toxicology, DNA adduct detection and quantitation.

. Western blot, ELISA, immunoprecipitation, ChIP.

. In vitro, in vivo cellular techniques - human, tumor cell culture;

transfection; stable cell line establishment and clone isolation.

. Cell assays to study gene function and cellular pathway response to

various stresses including carcinogens and therapeutics; cell

phenotype analysis (colony formation, migration, invasion,

proliferation, apoptosis, autophagy, etc.).

. Cellular imaging; confocal microscopy; immunohistochemistry.

. Ex vivo methods, xenografts, nude mice, mouse bioassays, knockouts,

tumor harvest.

. Handling carcinogens, chemotherapeutics and various other toxins and

biohazardous reagents.

TEACHING AND ACADEMIC SERVICE HISTORY

2010-2011 (PSU)

. Lecturer for Biochemistry 510 graduate course Carcinogenesis and

Chemoprevention

. Lecturer for Pharmacology 503 graduate course Molecular Pharmacology

2009-2010

. Lecturer for Pharmacology 503 graduate course Molecular Pharmacology

. Lecturer for Pharmacology 550 graduate course Pharmacogenomics and

Pharmacogenetics

2008-2009

. Lecturer for Biochemistry 510 graduate course Carcinogenesis and

Chemoprevention

. Lecturer for Genetics 597G course Genetic Applications of Biomedical

Problems

. Facilitator, Biological Basis of Disease Problem-based Learning

. Lecturer for Pharmacology 520 graduate course Principles of Drug

Action

. Lecturer for Pharmacology 503 graduate course Molecular Pharmacology

. Lecturer for Pharmacology 550 graduate course Pharmacogenomics and

Pharmacogenetics

. Director Pharmacology Departmental Seminar Series

. Co-Developer, Co-Director and Lecturer of Genetics 583 course Cancer

Genetics and Genomics

2007-2008

. Lecturer for Biochemistry 510 graduate course Carcinogenesis and

Chemoprevention

. Lecturer for Pharmacology 520 graduate course Principles of Drug

Action

. Director and Lecturer for Pharmacology 503 graduate course Molecular

Pharmacology

. Facilitator, Neural & Behavior Science Problem-based Learning

. Facilitator, Biological Basis of Disease Problem-based Learning

2006-2007

. Lecturer for Pharmacology 520 graduate course Principles of Drug

Action

. Lecturer for Biochemistry 510 graduate course Carcinogenesis and

Chemoprevention

. Lecturer for Genetics 597G course Genetic Applications of Biomedical

Problems

. Facilitator, Hematology/Oncology Problem-based Learning

. Lecturer for Pharmacology 503 graduate course Molecular Pharmacology

. Lecturer for Pharmacology 550 graduate course Pharmacogenomics and

Pharmacogenetics

2005-2006

. Lecturer for Biochemistry 510 graduate course Carcinogenesis and

Chemoprevention

2004-present

. Advisory Committee, Functional Genomics Core Facility

2002-2004 (IFCP)

. Operations Committee

2000-2001

. Seminar Committee

1999 (MCO)

. Lecturer for graduate course Fundamentals of Oncology

1998-2000

. Faculty Senator, Department of Pathology

1998

. Lecturer for graduate course Genes and the Biology of Cancer

1996

. Lecturer for graduate course Genes and the Biology of Cancer

Contact this candidate